StockNews.com began coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research note published on Saturday. The brokerage issued a hold rating on the stock. JNCE has been the subject of several other reports. Sumitomo Mitsui Financial Group reissued a neutral rating on shares of Jounce Therapeutics in a research report on […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 2,280,000 shares, a drop of 28.3% from the March 15th total of 3,180,000 shares. Approximately 5.2% of the shares of the stock are short sold. Based on an average daily […]
Should You Buy or Sell Jounce Therapeutics Stock? Get The Latest JNCE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
StockNews.com began coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report sent to investors on Friday. The firm issued a hold rating on the stock. A number of other brokerages also recently issued reports on JNCE. Piper Sandler downgraded Jounce Therapeutics from an overweight rating to a neutral rating in […]